尽管盈利略有下滑，Immunovant股价仍上涨，而Immunome因癌症治疗进展创下12个月来的最高点。 Immunovant shares rose despite a slight earnings miss, while Immunome hit a 12-month high on cancer therapy progress.

尽管交易量低于平均水平,但Immunovant (IMVT) 股价在2025年12月11日上8.1%,至25.46美元,季度亏损0.73美元,略低于预期. Immunovant (IMVT) shares rose 8.1% to $25.46 on December 11, 2025, despite below-average trading volume, following a quarterly loss of $0.73 per share slightly missing estimates. 这家公司开发了针对肌痛性肌痛等自身免疫性疾病的单克隆抗体, 分析师对其看法不一, 普遍认为"适度购买"的目标价格为28.78美元. The company, developing monoclonal antibodies for autoimmune diseases like myasthenia gravis, has a mixed analyst outlook with a consensus "Moderate Buy" and a $28.78 average price target. 机构所有权占47.08%,市场上限为4.34亿美元。 Institutional ownership stands at 47.08%, with a market cap of $4.34 billion. 同时, IMNM(IMNM)创下12个月的20.65美元高位, 接近20.54美元, 因为分析师维持“Moderate Buy”(Moderate Buy)共识, 目标为25. 00美元。 Meanwhile, Immunome (IMNM) hit a 12-month high of $20.65, closing at $20.54, as analysts maintain a "Moderate Buy" consensus with a $25.00 target. 生物技术报告季度损失0.65美元,缺少估计数,并在临床和临床前阶段推进癌症治疗。 The biotech reported a quarterly loss of $0.65, missing estimates, and is advancing cancer therapies in clinical and preclinical stages.